Priyadarshini Balasubramanian, MD
Assistant Professor of Medicine (Endocrinology)Cards
About
Research
Publications
Featured Publications
Multidisciplinary strategies to treat severe hypoglycemia in hospitalized patients with diabetes mellitus reduce inpatient mortality rate: Experience from an academic community hospital
Kadayakkara D, Balasubramanian P, Araque K, Davis K, Javed F, Niaki P, Majumdar S, Buller G. Multidisciplinary strategies to treat severe hypoglycemia in hospitalized patients with diabetes mellitus reduce inpatient mortality rate: Experience from an academic community hospital. PLOS ONE 2019, 14: e0220956. PMID: 31393971, PMCID: PMC6687156, DOI: 10.1371/journal.pone.0220956.Peer-Reviewed Original ResearchConceptsPatient mortality ratesSevere hypoglycemiaReadmission ratesDiabetes mellitusMortality rateNotification ratesStandardized treatmentGeneral internal medicine wardsMultidisciplinary strategyPatient's medical teamInpatient mortality rateInternal medicine wardsICD-10 codesPost-intervention studyStandardization of treatmentGlucose measurementsAcademic community hospitalSame observation periodDiabetic patientsHospitalized patientsMedicine wardsRetrospective reviewPhysician notificationPoor outcomeSecondary diagnosisBaseline Cardiovascular Risk Factor Control in Patients With Type 2 Diabetes and Coronary Disease Versus Stroke: Secondary Analysis of Cardiovascular Outcome Trials
Balasubramanian P, Kernan W, Sheth K, Ofstad A, Rosenstock J, Wanner C, Zinman B, Mattheus M, Marx N, Inzucchi S. Baseline Cardiovascular Risk Factor Control in Patients With Type 2 Diabetes and Coronary Disease Versus Stroke: Secondary Analysis of Cardiovascular Outcome Trials. Stroke 2023, 54: 2013-2021. PMID: 37449424, PMCID: PMC10358436, DOI: 10.1161/strokeaha.122.042053.Peer-Reviewed Original ResearchConceptsCardiovascular risk factor controlRisk factor controlCoronary artery diseaseEMPA-REG OUTCOMECardiovascular outcome trialsType 2 diabetesRisk factorsOutcome trialsBlood pressureOdds ratioAntiplatelet/anticoagulant medicationsAntiplatelet/anticoagulant therapyDiabetes cardiovascular outcome trialsSuboptimal risk factor controlCardiovascular risk factorsRecurrent ischemic eventsDiastolic blood pressureSystolic blood pressureRespective odds ratiosFactor controlCross-sectional analysisLogistic regression modelsMacrovascular complicationsStatin useAnticoagulant medicationChapter 13 Sodium-glucose Co-transporter-2 inhibitors: a new era of cardioprotection and renoprotection
Balasubramanian P, Inzucchi S. Chapter 13 Sodium-glucose Co-transporter-2 inhibitors: a new era of cardioprotection and renoprotection. 2023, 337-363. DOI: 10.1016/b978-0-323-99991-5.00006-1.Peer-Reviewed Original ResearchSGLT2 inhibitorsType 2 diabetesSodium-glucose cotransporter 2 inhibitorsGlucose cotransporter 2 inhibitorsLarge cardiovascular outcome trialsInduction of glucosuriaRenal protective benefitsCardiovascular risk factorsGlucose-lowering medicationsCardiovascular outcome trialsCotransporter 2 inhibitorsClinical practice guidelinesMechanism of actionRenal benefitsCardiorenal benefitsDiabetes statusOutcome trialsBlood pressureChronic kidneyHeart failureRisk factorsLipid profileCardiovascular diseasePractice guidelinesBody weightEmpagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?
Balasubramanian P, Wanner C, Ferreira J, Ofstad A, Elsaesser A, Zinman B, Inzucchi S. Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition? Medicine Of Ukraine 2022, 48-52. DOI: 10.37987/1997-9894.2022.5-6(261-2).271666.Peer-Reviewed Original ResearchIncidence rate ratiosT2D patientsClinical trialsStone eventsGLP-1 receptor agonistsLarge cardiovascular outcome trialsEMPA-REG OUTCOMESGLT2 inhibitor empagliflozinCardiovascular outcome trialsProspective clinical trialsSGLT2 inhibitor useRisk of nephrolithiasisAnnual incidence rateRandomized clinical trialsType 2 diabetesRelative risk estimatesEmpagliflozin therapyInhibitor empagliflozinInhibitor useOutcome trialsDiabetes mellitusSGLT2 inhibitionReceptor agonistRisk factorsIncidence rateCalcitriol mediated hypercalcemia due to necrotizing sarcoid granuloma of the liver
Balasubramanian P, Kadayakkara DK, Soloway G, Laskin W, Majumdar S. Calcitriol mediated hypercalcemia due to necrotizing sarcoid granuloma of the liver. Int J Case Rep Images 2017;8(7):458–461.Peer-Reviewed Case Reports and Technical NotesAlbumin-Corrected Calcium and the Prevalence and Categories of Hypercalcemia in Hospitalized Patients With 1-Year Follow-Up of Undiagnosed Cases
Balasubramanian.P, S. K. Majumdar, Albumin-Corrected Calcium and the Prevalence and Categories of Hypercalcemia in Hospitalized Patients With 1-Year Follow-Up of Undiagnosed Cases, Endocrine Practice, Volume 27, Issue 4, 2021, Pages 279-285.Peer-Reviewed Original Research7418 Xanthoma Disseminatum - A Rare cause of Diabetes Insipidus
Balasubramanian P, Cohen J, Corbin Z, Panse G, Inzucchi S. 7418 Xanthoma Disseminatum - A Rare cause of Diabetes Insipidus. Journal Of The Endocrine Society 2024, 8: bvae163.1380. PMCID: PMC11454384, DOI: 10.1210/jendso/bvae163.1380.Peer-Reviewed Original ResearchCentral diabetes insipidusDiabetes insipidusSystem involvementXanthoma disseminatumOvernight water deprivation testPartial central diabetes insipidusCentral nervous system involvementPituitary stalk involvementDegree of hypopituitarismNon-Langerhans cell histiocytosisVariable degrees of hypopituitarismAnterior pituitary functionResolution of symptomsWater deprivation testNervous system involvementSymptoms of polyuriaMRI pituitaryStalk involvementPituitary involvementHypogonadotropic hypogonadismIV contrastSpontaneous regressionPituitary functionPituitary stalkSerum sodium7168 Papillary thyroid carcinoma co-existing with intrathyroidal metastasis from lung neuroendocrine tumor
Balasubramanian P, Ladenheim A, Gilani S, Gibson C, Kunz P. 7168 Papillary thyroid carcinoma co-existing with intrathyroidal metastasis from lung neuroendocrine tumor. Journal Of The Endocrine Society 2024, 8: bvae163.2027. PMCID: PMC11453623, DOI: 10.1210/jendso/bvae163.2027.Peer-Reviewed Original ResearchLung neuroendocrine tumorsPapillary thyroid carcinomaNeuroendocrine tumorsThyroid carcinomaPapillary thyroid cancerIntrathyroidal metastasisThyroid cancerThyroid metastasisPET-CTThyroid nodulesMetastatic lung NETsLow-risk thyroid cancerLeft thyroid noduleCentral neck dissectionFDG PET-CTMedullary thyroid carcinomaTreatment response evaluationIncidental thyroid nodulesInitiation of treatmentYear old femaleDiagnosed primary malignancyRate of FDGCalcitonin stainingFinal pathologyNeck dissection
Academic Achievements & Community Involvement
Clinical Care
Overview
Priyadarshini Balasubramanian, MD, is an endocrinologist who specializes in pituitary, adrenal, and thyroid diseases.
Dr. Balasubramanian says she was drawn to endocrinology because it’s not limited to one organ. “Most endocrine conditions have varied and interesting presentations involving multiple organ systems,” she says. “As a true lover of internal medicine, I like how its broad and yet specialized and multi-dimensional. It’s a cognitive specialty, where solving each problem is like solving a puzzle, and I like the mystery.”
Dr. Balasubramanian sees patients with pituitary, adrenal, and thyroid conditions including thyroid cancer primarily at Smilow Cancer Hospital’s Endocrine Cancers Program in New Haven and Trumbull. She also sees patients with type 1 and type 2 diabetes at Yale Diabetes Center in New Haven.
The best part of her job, she says, is developing long-term relationships with her patients.
“It’s gratifying to support my patients through various stages in their life. I enjoy being able to work with my patients and help them with their complex problems,” she says. “I like to make all information available to my patients and work with them to make an individualized plan to ensure the best possible outcome because there are many different treatment options they can choose from. However, I tell them that whatever option they choose, I will walk beside them to guide and support them through their journey.”
Dr. Balasubramanian’s research interests include pituitary diseases and cardiovascular complications of diabetes.
Clinical Specialties
Endocrinology
News
News
- January 23, 2023
Yale’s Endocrine Neoplasia Program Is Flourishing
- September 27, 2022
Welcome New Staff, Faculty, Fellows, Postgrads, Postdocs (September 2022)
- July 27, 2022
New Appointments & Promotions Within Department of Internal Medicine
- April 13, 2022
Meet Yale Internal Medicine: Priyadarshini Balasubramanian, MD
Get In Touch
Contacts
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.